APA (7th ed.) Citation

Marinkovich, M. P., Paller, A. S., Guide, S. V., Gonzalez, M. E., Lucky, A. W., Bağcı, I. S., . . . Krishnan, S. M. (2025). Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study of Patients with Dystrophic Epidermolysis Bullosa. American journal of clinical dermatology, 26(4), 623-635. https://doi.org/10.1007/s40257-025-00942-y

Chicago Style (17th ed.) Citation

Marinkovich, M. Peter, et al. "Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study of Patients with Dystrophic Epidermolysis Bullosa." American Journal of Clinical Dermatology 26, no. 4 (2025): 623-635. https://doi.org/10.1007/s40257-025-00942-y.

MLA (9th ed.) Citation

Marinkovich, M. Peter, et al. "Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study of Patients with Dystrophic Epidermolysis Bullosa." American Journal of Clinical Dermatology, vol. 26, no. 4, 2025, pp. 623-635, https://doi.org/10.1007/s40257-025-00942-y.